NVO · Novo Nordisk A S

Track NVO — free

$37.91 -0.40 (-1.04%) At close · Sep 30

Rebalance outlook locked

Market Cap

$171.37B

4.42B

Volume · Sep 30 21.56M Avg daily vol (3M) 12.35M

Up next

Next earnings call

Nov 5, 2026 Est · unconfirmed · in 5 wks

Q2 2026 earnings call transcript

call held Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$51.45B

Trailing 12 months

Net income (TTM)

$18.20B

Trailing 12 months

Revenue growth YoY

+2.1%

Year over year

Operating margin

43.1%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

6.9%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

−$14.54B

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

—

Year over year · more shares

Price change (1Y)

-31.0%

Trailing year

Short interest

0.6%

Latest settlement · 2.9 days to cover

View all 115 metrics

Equibles Research

our published analysis of this company

Research Thesis July 31, 2026

Novo Nordisk's 1.3 million Wegovy pill TRxs meet a 50% WAC cut — and the bear case still wins

Novo Nordisk is the only name in the GLP-1 bellwether set guiding negative adjusted-sales growth for 2026 (-4% to -12% at CER), even as Wegovy pill TRxs hit around 1.3 million in Q1 2026 and the 1 January 2027 WAC reset to USD 675 locks in further realised-price compression.

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High

Market backdrop VIX 16.3 · calm Equity put/call 0.53

Technical

price trend

Strong Sell

50 / 200-day cross Death cross

Price vs 200-day avg −17%

below

Price vs 50-day avg −16%

below

RSI (14) 29

oversold

MACD trend Negative

52-week position 9%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −16%

trailing

6-month return +1%

trailing

YTD return −25%

this year

Relative strength −11%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) Death cross

50d $45 › 200d $46 — 200d above 50d

Institutional flow Accumulating

+6% holders QoQ · +216 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.60% of float · ▼ -16.8% MoM · 2.9 days cover

Volume signal Reversal watch

High volume on a down day — possible exhaustion

Institution breadth Steady

1,369 holders — mid 3-yr range

Squeeze score 35

low risk · 0–100

Fundamentals

Limited

Not enough data for a confident read.

Quant / Vol

risk profile

Very High

Volatility 46%

annualized · 1-yr

Max drawdown −45%

past year

ATR 3.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed Sep 30, 2025

Negative impact on full-year operating profit growth · 2026 3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell

5 · 2 · 0

50 / 200-day cross

Death cross Bearish

Price vs 200-day avg

−17% Bearish

Price vs 50-day avg

−16% Bearish

RSI (14)

29 Neutral

MACD trend

Negative Bearish

52-week position

9% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) Death cross

50d $45 › 200d $46 — 200d above 50d

Institutional flow Accumulating

+6% holders QoQ · +216 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.60% of float · ▼ -16.8% MoM · 2.9 days cover

Volume signal Reversal watch

High volume on a down day — possible exhaustion

Institution breadth Steady

1,369 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $35 Now $38 · 9% Range high $64

vs 200-day avg -17% vs 50-day avg -16% 50-day below 200-day death cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - General — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
NVO Novo Nordisk A S this stock	$171.37B	-25.5%	—	—	0.6%
LLY ELI LILLY & Co	$1.11T	+7.7%	+44.7%	39.7	0.8%
JNJ Johnson & Johnson	$653.61B	+27.9%	+6.0%	31.5	0.9%
ABBV AbbVie Inc.	$466.80B	+14.5%	+8.6%	74.6	1.1%
MRK Merck & Co., Inc.	$367.07B	+38.0%	+1.3%	119.0	1.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

1,369

% held: 9.3%
Net QoQ: +3.9M sh
Top holder: Dodge & Cox

Held Float

View

Held by Funds

Fund positions

191

View

Short & Settlement

Short Interest Falling

Shares short

26.3M

Days to cover: 2.9d
Change: -5.3M sh

View

Short Volume

Short vol %

47%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

13.0K

Value: $572.1K
As of: Sep 11, 2026

View

Off-Exchange

Off-exchange %

43.9%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Lisa McClain

Amount: $1.0K–$15.0K
Traded: Oct 31, 2025

View

Filings

SEC Filings

Latest

6-K

Filed: Sep 28, 2026
This year: 61

View

Proposed Sales

Value

$2.0M

Shares: 921.9K
Filed: May 30, 2025

View

Earnings & Events

Earnings Calls

Last call

Aug 5, 2026

View

Investor Relations

Upcoming events

View

Performance

	5D	20D	120D	MTD	YTD
NVO	-0.7%	-16.0%	+1.3%	-16.4%	-25.5%
SPY	-0.7%	+0.1%	+12.2%	-0.6%	+11.8%
vs SPY	0.0%	-16.1%	-10.9%	-15.8%	-37.3%

Key facts CIK 353278 CUSIP 670100205 13F (30d) 31 filings 18 filers Visit website Investor relations

NVO · Novo Nordisk A S

Price & Indicators

Up next

Metrics snapshot

Equibles Research

Equibles Rating

Guidance & track record

Technicals

Versus peers

At a glance

Performance